GKSL Reports No Deviation in Public Issue Fund Utilization for Q3 FY26
Gujarat Kidney And Super Speciality Limited confirms no deviation in the utilization of ₹2,508,000,000 raised from its public issue for the quarter ended December 31, 2025. Funds were allocated to acquisitions, capital expenditure, and debt repayment.
This is a standard regulatory filing and does not indicate any new business development or financial performance change, hence the impact is low.
The announcement is a routine compliance filing confirming no deviation in fund utilization, which is a neutral event for the company.
Gujarat Kidney And Super Speciality Limited (GKSL) has submitted a statement to BSE Limited and National Stock Exchange of India Limited confirming no deviation or variation in the utilization of proceeds from its public issue. This statement pertains to the third quarter ended December 31, 2025, as required by Regulation 32 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015.
The company raised ₹2,508,000,000 (250.80 Crore) through an equity shares issue on December 24, 2025. The funds were allocated towards several objects including the proposed acquisition of Parekhs Hospital Private Limited, part payment for Ashwini Medical Centre, acquisition of additional shareholding in its subsidiary Harmony Medicare Private Limited, funding capital expenditure for a new hospital for women's healthcare, purchasing robotics equipment, full or part repayment of outstanding borrowings, and funding inorganic growth and general corporate purposes.
The statement explicitly confirms that there were no deviations or variations in the use of these funds for the quarter ended December 31, 2025. The Audit Committee and auditors have also commented that there were no issues found. The submission was made on February 14, 2026.
What to do with a filing like this
Gujarat Kidney And Super Speciality Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Kidney And Super Speciality Limited. Read the original for the full detail.